OTSUKA PHARMACEUTICAL CO., LTD.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Public, Subsidiary
- Established
- 1964-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.otsuka.co.jp
Comparison Study Between C13-CAC Breath Test and 24-hour Gastric pH Monitoring
Phase 2
Completed
- Conditions
- Gastric Acid-related DiseasesHealthy
- Interventions
- First Posted Date
- 2014-08-25
- Last Posted Date
- 2015-05-04
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT02225067
- Locations
- 🇯🇵
OPHAC Hospital, Osaka, Japan
Prospective Observational Study of Clostridium Difficile Infection in Asian Pacific Countries
Completed
- Conditions
- Clostridium Difficile Infection
- Interventions
- Other: CDI Pts
- First Posted Date
- 2014-08-22
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 600
- Registration Number
- NCT02223715
A Multicenter Open-label Study Investigating the Pharmacokinetics and Safety of Aripiprazole IM Depot Formulation (OPC-14597 IMD) During Repeated Administration by Injection Into the Deltoid Muscle in Patients With Schizophrenia
- First Posted Date
- 2014-08-20
- Last Posted Date
- 2021-01-25
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 17
- Registration Number
- NCT02220712
Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type
Phase 3
Terminated
- Conditions
- Agitation Associated With Dementia of the Alzheimer's Type
- Interventions
- Drug: 3 mg/dayDrug: 6 mg/dayDrug: 2 mg/dayDrug: Placebo (0 mg/day)
- First Posted Date
- 2014-06-20
- Last Posted Date
- 2017-10-16
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT02168920
Pharmacokinetic Study of OPC-1085EL Ophthalmic Solution in Healthy Male Adult Volunteers
Phase 1
Completed
- Conditions
- Ocular HypertensionGlaucoma
- Interventions
- Drug: OPC-1085EL ophthalmic solution
- First Posted Date
- 2014-04-09
- Last Posted Date
- 2015-04-22
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT02108288
Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
Phase 3
Completed
- Conditions
- Ocular HypertensionGlaucoma
- Interventions
- Drug: OPC-1085EL ophthalmic solution
- First Posted Date
- 2014-04-07
- Last Posted Date
- 2015-12-28
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 193
- Registration Number
- NCT02105285
Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
Phase 3
Completed
- Conditions
- Ocular HypertensionGlaucoma
- Interventions
- Drug: OPC-1085EL ophthalmic solution
- First Posted Date
- 2014-04-07
- Last Posted Date
- 2015-12-21
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 237
- Registration Number
- NCT02105272
A Bioequivalence Study of ASC-01 Placebo (Aripiprazole 0 mg/Sertraline 100 mg) and Sertraline Tablet in Healthy Male Subjects
- First Posted Date
- 2014-03-17
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT02088697
- Locations
- 🇯🇵
Osaka Pharmacology Clinical research Hospital, Osaka, Japan
A Phase 2 Trial of Rebamipide Liquid to Determine the Effective Dose for Prevention of Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer
Phase 2
Completed
- Conditions
- Head and Neck Cancer
- Interventions
- First Posted Date
- 2014-03-12
- Last Posted Date
- 2021-10-18
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 94
- Registration Number
- NCT02085460
A Trial to Determine the Safety, Pharmacokinetics, and Efficacy of OPC-108459 Administered as a Single Intravenous Dose to Patients With Paroxysmal or Persistent Atrial Fibrillation (AF)
- First Posted Date
- 2014-02-21
- Last Posted Date
- 2018-11-05
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT02069119
© Copyright 2025. All Rights Reserved by MedPath